重大事件即時報告 8-K 2026-06-22

CervoMed Inc.完成1,000萬美元直接登記發行，每股定價4美元

AI 繁中摘要

CervoMed Inc.（納斯達克代碼：CRVO）於2026年6月22日提交8‑K申報文件，宣佈完成一項已於早前公佈的「按市價直接登記發行」（Registered Direct Offering）。該發行根據納斯達克規則定價，以每股4.00美元銷售2,500,000股普通股，集資總額約1,000萬美元（未扣除承銷折扣及其他費用）。股份已於同日完成交割。

是次發行使公司即時獲得營運資金，有助支持其研發管線及一般企業用途。對現有股東而言，該發行帶來約5.5%的攤薄效應（按發行前股數推算），但管理層認為此舉有助於加快核心項目的推進。市場反應暫時平穩，投資者需留意後續資金運用披露及股價波動風險。

展開英文正文

crvo20260622_8k.htm
 
 
 

false
0001053691

0001053691

2026-06-22
2026-06-22

 
 
 
 UNITED STATES
 
 

 SECURITIES AND EXCHANGE COMMISSION
 

 Washington, D.C. 20549
 

 ___________________________

  

 FORM 8-K
 

 ___________________________

  

 CURRENT REPORT
 

 Pursuant to Section 13 or 15(d)
 

 of The Securities Exchange Act of 1934
 

  

 June 22, 2026
 

 Date of Report (Date of earliest event reported)
 

 ___________________________

  

 CervoMed Inc.
 

 (Exact name of registrant as specified in its charter)
 

 ___________________________

  

 
 Delaware
 
001-37942
 
30-0645032

 

 
 (State or other jurisdiction
 

 of incorporation)
 
 

 (Commission
 

 File Number)
 
 

 (I.R.S. Employer
 

 Identification No.)
 

 

  
 
 
 
 

 

 20 Park Plaza, Suite 424
Boston, Massachusetts
 
02116

 

 
 (Address of principal executive offices)
 
 

 (Zip Code)
 

 

 
  

 Registrant’s telephone number, including area code: (617) 744-4400
 

  

 Not applicable
 

 (Former name or former address, if changed since last report)
 

 ___________________________

  

 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  

 
 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 
  

 
 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 
  

 
 ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 
  

 
 ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
  

 
 
 Title of each class
 
 

 Trading
 

 Symbol(s)
 
 

 Name of each exchange
 

 on which registered
 

 

 Common Stock, $0.001 par value
 
CRVO
 
NASDAQ Capital Market

 

 
  

 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

  

 Emerging growth company  ☐
 

  

 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

  

 
 
 
 
 1

 

 
 

 

 Item 7.01. Regulation FD Disclosure.
 

  

 On June 22, 2026, CervoMed Inc. (the “Company”) issued a press release announcing the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,500,000 shares of the Company’s common stock at a purchase price of $4.00 per share of common stock (the “Offering”).

  

 The press release, which is furnished as Exhibit 99.1 to this Current Report on Form 8-K, is incorporated herein by reference. The information in or incorporated by reference into this Item 7.01 and Exhibit 99.1 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

  

 Item 8.01. Other Events.
 

  

 On June 22, 2026, the Company closed the Offering.

  

 
 
 2

 

 
 

 

  

 Item 9.01. Financial Statements and Exhibits.
 

  

 (d) Exhibits
 

  

 
 Exhibit 
 
No.
 
Description

 

  
 
 

 

 99.1
 
Press Release.

 

  
 
 

 

 104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
  

 
 
 3

 

 
 

 

  

 SIGNATURES
 

  

 Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

 
  
CervoMed Inc.
 

 

  
 
 
 
 

 

 Date: June 22, 2026
By:
/s/ William Elder
 

 

  
 
Name:
William Elder
 

 

  
 
Title:
Chief Financial Officer & General Counsel
 

 

 
  

 
 4